Fierce Biotech Names ROME Therapeutics as One of its “Fierce 15” Biotech Companies of 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ROME Therapeutics, a biotechnology company harnessing the power of the repeatome in drug development, today announced that it has been named by Fierce Biotech as one of 2020’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
ROME was founded to develop novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” ROME was launched in April 2020 with $50M Series A funding led by GV and ARCH Venture Partners with participation from Partners Innovation Fund.
“We are honored to be selected as a Fierce 15 company, recognizing ROME’s mission to unlock the uncharted territory of the repeatome and discover a new class of therapies for patients with serious debilitating diseases,” said Rosana Kapeller, M.D., Ph.D., CEO, President and Co-founder of ROME Therapeutics. “In a short amount of time, our growing team of ‘Romans’ has generated significant momentum for our lead programs and research platform. We are thankful for the continued support of our founders, collaborators, advisors and investors in pursuit of this mission.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is Fierce Biotech’s 18th annual Fierce 15 selection.
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning. ROME was launched in April 2020 and was incubated at GV, in collaboration with ARCH Venture Partners and Partners Innovation Fund. ROME is based in Cambridge, Mass. For more information, please visit www.rometx.com.
About Fierce Biotech
Fierce Biotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200928005116/en/
Ten Bridge Communications
Source: ROME Therapeutics
View this news release online at: